Traws Pharma’s (TRAW) Sell (D-) Rating Reiterated at Weiss Ratings

Weiss Ratings reiterated their sell (d-) rating on shares of Traws Pharma (NASDAQ:TRAW) in a report published on Thursday,Weiss Ratings reports.

Traws Pharma Stock Performance

Shares of NASDAQ:TRAW opened at $2.57 on Thursday. The company has a market cap of $18.31 million, a P/E ratio of 0.03 and a beta of 1.69. The stock’s 50-day moving average is $2.17 and its 200-day moving average is $1.74. Traws Pharma has a 52-week low of $0.97 and a 52-week high of $19.44.

Traws Pharma (NASDAQ:TRAW) last issued its quarterly earnings results on Thursday, August 14th. The company reported ($0.11) earnings per share (EPS) for the quarter, beating the consensus estimate of ($8.75) by $8.64. The company had revenue of $2.73 million for the quarter, compared to the consensus estimate of $0.06 million. Traws Pharma had a negative return on equity of 1,812.48% and a net margin of 3,028.25%.

Institutional Investors Weigh In On Traws Pharma

An institutional investor recently bought a new position in Traws Pharma stock. Adage Capital Partners GP L.L.C. bought a new position in shares of Traws Pharma, Inc. (NASDAQ:TRAW) during the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 330,000 shares of the company’s stock, valued at approximately $759,000. Adage Capital Partners GP L.L.C. owned approximately 6.19% of Traws Pharma as of its most recent SEC filing. Hedge funds and other institutional investors own 7.95% of the company’s stock.

Traws Pharma Company Profile

Traws Pharma, Inc, a clinical stage biopharmaceutical company, focuses on developing small molecule oral product candidates for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID19 that are designed to address treatment resistance, such as TRX01 (travatrelvir), a Mpro/3CL inhibitor in development for the treatment of COVID19; and TRX100 (viroxavir), an endonuclease inhibitor in development for the treatment of pandemic influenza.